Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to 0.76.

  • Adma Biologics' Equity Ratio rose 2772.08% to 0.76 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.76, marking a year-over-year increase of 2772.08%. This contributed to the annual value of 0.71 for FY2024, which is 7388.62% up from last year.
  • Per Adma Biologics' latest filing, its Equity Ratio stood at 0.76 for Q3 2025, which was up 2772.08% from 0.71 recorded in Q2 2025.
  • Adma Biologics' 5-year Equity Ratio high stood at 0.76 for Q3 2025, and its period low was 0.33 during Q3 2022.
  • In the last 5 years, Adma Biologics' Equity Ratio had a median value of 0.44 in 2024 and averaged 0.51.
  • Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 2245.14% in 2022, then skyrocketed by 7388.62% in 2024.
  • Over the past 5 years, Adma Biologics' Equity Ratio (Quarter) stood at 0.51 in 2021, then decreased by 14.66% to 0.44 in 2022, then fell by 5.82% to 0.41 in 2023, then soared by 73.89% to 0.71 in 2024, then grew by 6.16% to 0.76 in 2025.
  • Its last three reported values are 0.76 in Q3 2025, 0.71 for Q2 2025, and 0.73 during Q1 2025.